WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & Solutions
Services & Solutions - Investor Relations
Investor Relations - News & Resources
News & Resources
WuXi XDC Granted ISO 22301 Certification
Shanghai, China, April 10, 2025 WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, announced that it has successfully achieved ISO...WuXi XDC and Mabsoft Therapeutics Form Strategic Partnership to Accelerate Development of Next-Generation Immune-Stimulating Antibody Conjugates (ISACs)
Shanghai, April 3, 2025 – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced a strategic partnership with Mabsoft...WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024
Revenue increased by 90.8% YoY to RMB 4,052 million Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023 Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of...
WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025
Shanghai, China, March 13, 2025 — WuXi XDC Cayman Inc. (“WuXi XDC”, or the “Company”, stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization)specializing in antibody-drug conjugates (ADCs) and other bioconjugates,...
WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs
SHANGHAI, China and SEOUL, South Korea, Mar 11, 2025—WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?